Call Us Now : Office: (734) 930-0461

Corporate Profile

Accumed develops and commercializes innovative tools for interventional medicine. Accumed’s goal is to provide devices that simplify existing medical procedures – increasing patient comfort and saving the clinician time.

The Company interacts with clinical teams to convert good ideas into novel new devices. Throughout its history, Accumed has worked hard to be responsive to the inventing clinician, taking the lead from our founder, Dr. William O’Neill.

Accumed Corporate Team

Officers

Marilyn Katz-Pek, President and CEO
Patrick J. O’Neill, JD, Secretary
Maria Callaghan, JD, CPA, Treasurer

Board Members

 William W. O’Neill, MD
Chairman and Chief Scientific Officer, is also Medical Director, Structural Heart Disease Center, Henry Ford Hospital, Detroit, MI. Prior to returning to Michigan and Henry Ford Hospital, Dr. O’Neill was the Chief Medical Officer, the Executive Dean for Clinical Affairs, and Professor of Medicine at the University of Miami Health System. Dr. O’Neill received his MD from Wayne State University School of Medicine and completed a cardiology fellowship at the University of Michigan Medical Center.

Patrick J. O’Neill, CEO, Secretary
An attorney by training, Mr. O’Neill is a highly successful businessman who founded and serves as CEO of the NSI Group of Huntington Woods, Michigan.  In that capacity, Mr. O’Neill is CEO or controlling shareholder of several companies. Mr. O’Neill holds a Bachelor of Science degree in Engineering from the U.S. Military Academy, and a Juris Doctor degree from Wayne State University. He is a member in good standing of the State Bar of Michigan.  Mr. O’Neill and Dr. O’Neill are brothers.

Marilyn (Mickey) Katz Pek, President and CEO
Ms. Katz-Pek has an extensive background and experience in the start up environment.  She is a founder and (retired) principal of Biotechnology Business Consultants, LLC (renamed BBCetc), advisors and managers to start-up and development stage companies.  Mickey is a co-founder of the Michigan Biotechnology Association (now MichBio), and served as Chairperson of the Michigan Center for High Technology.   She is on the Board of Directors of NSF International Holdings.  Ms.Katz-Pek is a major shareholder of Accumed.

Maria Callaghan, JD, CPA, Treasurer
Ms. Callaghan holds a BBA degree in accounting from the University of Michigan, Ann Arbor, Michigan, and a Juris Doctor in tax law from Wayne State University, Detroit, Michigan. She is a CPA and has worked on the staff of two of the Big Four accounting firms. Ms. Callaghan currently serves as Tax Director for a multi-billion dollar division of one of the largest industrial corporations in the nation.

Paul Zalesky, PhD.
Dr. Zalesky is an entrepreneur in the bio-medical arena. He is a founder and served as CEO and President of LumexRx, a development stage company focused on light-based therapy in Gastroenterology. In that role, Dr. Zalesky: raised private equity financing; recruited and managed key technical staff and consultants; directed efforts to meet the Clinical, Regulatory, Quality and Marketing efforts of the Company as well as the formulation and implementation of strategies and plans. Dr. Zalesky holds a Bachelor of Science degree from the University of Notre Dame in Aerospace Engineering; a Master of Science degree from the University of Michigan in Aerospace Engineering; and a PhD. from the University of Michigan in Biomedical Engineering. He also is a co-inventor on more than 16 U.S. and International patents, encompassing intravascular ultrasound, coronary and cerebrovascular catheters and guidewires, electromechanical imaging and control systems, next generation cardiopulmonary bypass systems, Oxygen supersaturated solutions’ preparation and vascular delivery, and photodynamic therapy devices and systems. Dr. Zalesky has led or co-authored approximately 20 articles in medical and research journals, encompassing cardiovascular technology and devices, bench and animal model tests on new technologies for heart-related diagnosis and therapy, and clinical (patient) studies on new devices and procedures.

James M. Koert
Mr. Koert is an experienced businessman in the biomedical arena. He is one of the founders of Benecor Heart Systems Inc. serving as its president for many years. He has served in various high level management positions at several large, publicly traded biomedical companies. Mr. Koert served as Senior Vice President of Abiomed, Inc., the developer of the nation’s first artificial heart. Mr. Koert holds a Bachelor of Science and Master of Science in Chemistry, and an MBA degree from the University of Michigan. He is a major shareholder of Accumed and a former president of the Company.

Christopher Benham
Christopher Benham is a businessman who was trained as an engineer. He has been in leadership positions in various companies in his business career serving as CEO, President, CFO and Chief of Marketing in numerous firms, often times in “turn around” situations. Currently, Mr. Benham is the CEO of ComCom Systems Inc., a software development and services firm, located in Clearwater, Florida. Mr. Benham holds a Bachelor of Science degree in Engineering from the U.S. Military Academy at West Point, New York and an MBA from Averett University Danville, Virginia.

Management

Marilyn (Mickey) Katz-Pek, President and CEO
Ms. Katz-Pek returned to active management of Accumed in October 2011 and became President and CEO of Accumed Systems, Inc. in June 2012. Ms. Katz-Pek has been a member of the Accumed Board since 1996. In 1993, she assisted with the sale of the Everest™ balloon inflation device to Medtronic, and was President of Accumed from 1997-2000, leading the Company to the receipt of initial grants from the National Institutes of Health and the Michigan Economic Development Corporation for development of the Thermal Sensing system. During that period, Accumed brought to market the Accumed Wrist Positioning Splint and Radial Artery Hemostasis Band. Ms. Katz-Pek was the lead negotiator for Accumed in the sale of the wrist splint technology to Vascular Solutions, Inc. in June 2012.

Joseph Korotko, Director of Product Development and Engineering
Mr. Korotko is an original employee of Accumed, leads the product development effort across all Accumed entities, and is one of the inventors of the TSS. Mr. Korotko will transition to full-time at AccuTherm upon funding. Joe has a Master of Science in Bioengineering from the University of Michigan. He spent 9 years at an orthopedic medical device firm prior to joining Accumed Systems in 1998.

Scientific and Medical Advisors

William O’Neill, MD
In addition to Dr. O’Neill’s role as Chairman of the Board of Directors, he leads a team of permanent and ad hoc scientific and medical advisors. An author of more than 700 peer reviewed publications, Dr. O’Neill is an international leader in the field of interventional cardiology and in the research of new medicines and techniques to diagnose and treat obstructed heart arteries. He has led and participated in countless device and drug clinical trials including, most recently, percutaneous valve replacement. Dr. O’Neill has extensive, long-standing relationships with key individuals in all segments of the cardiology business, most importantly the research community.

Mauricio G. Cohen, MD, FACC, FSCAI
An interventional cardiologist and a Tenured Associate Professor of Medicine at the University of Miami Miller School of Medicine. He attended Medical School at Universidad Nacional de Tucumán in Argentina. He did his medicine/cardiology training at Hospital Italiano de Buenos Aires in Argentina and subsequently did an interventional cardiology and clinical research fellowship at Duke University Medical Center and the Duke Clinical Research University. In 2000, he joined the interventional cardiology staff at Hospital Italiano de Buenos Aires, one of the leading medical institutions in South America, and also worked as a clinical trials reviewer for ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnologías Médicas – National Administration for Medicines, Foods and Medical Technologies) between 2000 and 2002.

In 2003, he joined the Division of Cardiology at University of North Carolina at Chapel Hill where he was part of the interventional faculty and the director of cardiology clinical trials. Dr. Cohen is currently the Director of the Cardiac Catheterization Laboratory at University of Miami Hospital. He conducted a multicenter phase IIa multicenter clinical trial and acted as local PI in more than 10 multi- and single-center clinical trials. In 2011, he received the “Stop Heart Disease Researcher of the Year Award” by the Florida Heart Research Institute. The Society for Cardiac Angiography and Interventions recognized Dr. Cohen as an “Emerging Leader” in the field of interventional cardiology. Dr. Cohen has published more than 60 papers in peer-reviewed journals. His major clinical and research interests include novel antithrombotic strategies, transradial cardiac catheterization and intervention, transcatheter valve therapies, and health disparities. He is an established national and international leader in transradial catheterization and interventions.